Squarepoint’s Cardio Diagnostics CDIO Stock Holding History

Squarepoint’s Portfolio CDIO Stock Details CDIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,304	Closed	-$97.4K	–	4095
2023 Q4	$97.4K	Buy	+1,304	New	+$45.1K	﹤0.01%	3758

Other funds holding CDIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

CSC

Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return

Squarepoint's CDIO Position: Q1 2024 in Review

Squarepoint sold out of Cardio Diagnostics (CDIO) in Q1 2024, closing a stake of 1,304 shares — an estimated $97.4K sold.

Squarepoint first reported a position in CDIO in Q4 2023 and held it in 1 quarter. The position peaked at $97.4K in Q4 2023. 14 funds tracked by Wall St. Rank hold CDIO as of Q1 2024.

Squarepoint reported no remaining Cardio Diagnostics position as of Q1 2024 after selling out during the quarter.
Squarepoint sold 1,304 Cardio Diagnostics shares in Q1 2024, an estimated $97.4K.
Squarepoint first reported a position in Cardio Diagnostics in Q4 2023 and held it in 1 quarter.
Squarepoint's Cardio Diagnostics position peaked at $97.4K in Q4 2023.
14 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.